Camlin Fine Sciences · NSE: CAMLINFINE · BSE: 532834

Q1 FY22 results · Apr–Jun 2021

Camlin Fine Sciences reported revenue from operations of ₹330.83 crore (up 8.2% from Q1 FY21) and net profit of ₹23.78 crore (up 15.6% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a consolidated basis.

Consolidated · ₹ crore
Item	Q1 FY22	Q1 FY21	YoY	Q4 FY21	QoQ
Revenue from operations	330.83	305.74	+8.2%	326.62	+1.3%
Other income	10.55	0.47	23x	2.09	+404.0%
Total income	341.38	306.21	+11.5%	328.72	+3.9%
Profit before share of associates & JVs and tax	32.57	31.51	+3.4%	28.60	+13.9%
Share of profit/(loss) of associates & JVs	(0.02)	0.00		0.00
Net profit for the period	23.78	20.56	+15.6%	15.72	+51.3%
Attributable to shareholders of the company	22.36	15.39	+45.3%	14.27	+56.7%
EPS, basic (₹)	1.75	1.27	+37.8%	1.16	+50.9%
Net margin (%)	7.2	6.7		4.8

This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.

Standalone · ₹ crore
Item	Q1 FY22	Q1 FY21	YoY	Q4 FY21	QoQ
Revenue from operations	145.73	121.17	+20.3%	168.46	−13.5%
Other income	3.83	0.99	+286.7%	2.78	+37.7%
Total income	149.56	122.16	+22.4%	171.24	−12.7%
Profit before tax	6.97	5.10	+36.5%	5.90	+18.1%
Net profit for the period	4.73	3.81	+24.2%	2.14	+121.6%
EPS, basic (₹)	0.37	0.31	+19.4%	0.17	+117.6%
Net margin (%)	3.2	3.1		1.3

Consolidated

Filed with BSE: 13 Aug 2021, 16:05 IST
Board meeting: 13 Aug 2021
Period: 01 Apr 2021 to 30 Jun 2021
Review status: Unaudited
Source: XBRL filing on BSE

Standalone

Filed with BSE: 13 Aug 2021, 16:05 IST
Board meeting: 13 Aug 2021
Period: 01 Apr 2021 to 30 Jun 2021
Review status: Unaudited
Source: XBRL filing on BSE